PCOM Professor Weighs in on Possible Alzheimer's CauseMarch 9, 2016
Dr. Balin is an internationally-recognized expert in the field of Alzheimer's Disease
An editorial published online March 8 in the Journal of Alzheimer’s Disease stresses the urgent need for further research and for clinical trials of anti-microbial
agents to treat Alzheimer's disease. This major call for action is based on substantial
published evidence indicating that certain microbes –a specific virus and two specific
types of bacteria—are major causes of the disease.
The editorial summarizes the abundant data implicating these microbes, but the authors
claim that until now, this work has been largely ignored, or else dismissed as controversial—despite
the dearth of contradictory evidence. The authors—31 senior scientists and clinicians
from around the world—say that because of this dismissal, proposals for the funding
of clinical trials have been refused, even though more than 400 clinical trials for
Alzheimer's based on other concepts were carried out over a recent 10-year period.
All were unsuccessful.
Brian Balin, PhD, professor and chair, is one of the editorial’s authors, and the only one from a Philadelphia institution.
“We have been studying and reporting on an infectious link to Alzheimer’s disease
for the past 18 years yet acceptance of this approach has been slow in coming,” said
Dr. Balin. “We need to realistically consider how pathogens invade our nervous system
to contribute to major neurological deficits. It is very similar to what we are facing
currently in the Americas with Zika virus infection associated with microcephaly and
Guillain-Barre Syndrome. We cannot delay as Alzheimer’s disease is taking an enormous
toll on the world’s aging population. “
In the editorial, the authors state that opposition to the microbial concepts resembles
the fierce resistance to studies some years ago that linked viruses to certain types
of cancer, and a bacterium to stomach ulcers. The authors argue that those concepts
were ultimately proved valid, leading to successful clinical trials and the subsequent
development of appropriate treatments.
“In consideration of the great social and financial impact of Alzheimer’s disease,
and the slow progress to a cure, it is imperative for the field to be open to vigorously
explore alternative approaches that are supported by experimental findings,” said
George Perry, PhD, a neuroscientist at the University of Texas at San Antonio and
editor-in-chief of the Journal of Alzheimer’s Disease.
About Philadelphia College of Osteopathic Medicine
Founded in 1899, Philadelphia College of Osteopathic Medicine (PCOM) has trained thousands
of highly competent, caring physicians, health practitioners and behavioral scientists
who practice a “whole person” approach to care—treating people, not just symptoms.
PCOM operates three campuses (PCOM, PCOM Georgia and PCOM South Georgia) and offers doctoral degrees in clinical psychology, educational psychology, osteopathic
medicine, pharmacy, physical therapy and school psychology, and graduate degrees in
applied behavior analysis, applied positive psychology, biomedical sciences, forensic
medicine, medical laboratory science, mental health counseling, non profit leadership
and population health management, organizational development and leadership, physician
assistant studies, school psychology, and public health management and administration.
PCOM students learn the importance of health promotion, research, education and service
to the community. Through its community-based Healthcare Centers, PCOM provides care
to medically underserved populations. For more information, visit pcom.edu or call 215-871-6100.
For more information, contact:
Associate Director, News and Media Relations
Office: 215-871-6304 | Cell:
Connect with PCOM